GeneDx Holdings Corp.
NASDAQ:WGSMedical - Healthcare Information Services
+$1.52 today
- Market cap
- $1.56B
- Beta
- 1.97
- P/E (TTM)
- -21.8
- EPS (TTM)
- -$2.65
Volume 1.71M
Average 1.28M
WGS Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
GeneDx Holdings Corp.NASDAQ: WGS
Accounts Payables · Q2 FY2026 · quarter ended Jun 2026
Accounts payables outflow grows to $602K
Q2 FY2026 accounts payables was $602K, compared with $0 a year earlier. Trailing-twelve-month accounts payables was -$5.65M. Over 3 fiscal years it compounded at -29.5% a year.
Context
- Accounts payables amounted to 2.8% of revenue in FY2025, down 3.9 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly accounts payables holds near $602K or moves back toward the trailing-twelve-month quarterly average of -$1.41M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 12.1M USD
- Year-over-year change
- +159.1%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.1M | +159.1% |
| FY2024 | 2024-12-31 | (20.46M) | +56.4% |
| FY2023 | 2023-12-31 | (46.95M) | -236.3% |
| FY2022 | 2022-12-31 | 34.46M | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Payables vs competitors
How WGS compares with its peers on the latest reported figures
- WGS's LTM Jun 2026 accounts payables of $5.65M is the 3rd largest of the 9 companies compared; the peer median is $1.26M.
- Its year-over-year change of -882.7% is the lowest of 7, against a peer median of +82.9%.
- Accounts payables amounts to 1.2% of revenue for WGS, versus a peer median of 1.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $16.49M | -289.5% | — | 2.2% | |
| LTM Mar 2026 | $5.66M | +269.6% | +74.2% | 1.7% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $5.65M | -882.7% | -29.5% | 1.2% |
| LTM Mar 2026 | $4M | +385.7% | -26.3% | 0.5% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $3.33M | — | — | 0.8% |
| LTM Mar 2026 | $1.73M | +235.6% | +13.8% | 2.7% | |
| LTM Mar 2026 | $800K | -69.8% | — | 0.2% | |
| FY2025 | $550K | — | — | 0.5% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $337K | -70.4% | +107.3% | 17.3% |
| Peer median (excluding WGS) | $1.26M | +82.9% | +44.0% | 1.3% | |
Competitors are the stored peer set for WGS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (245.39M) | (548.98M) | (175.77M) | (52.29M) | (21.02M) |
| Depreciation & Amortization | 21.81M | 59.31M | 33.73M | 21.95M | 25.22M |
| Deferred Income Tax | 0 | (49.12M) | (926K) | (343K) | 0 |
| Stock-Based Compensation | 219.42M | 41.98M | (326K) | 9.14M | 32.16M |
| Change in Working Capital | 8.08M | 36.13M | (38.24M) | (24.75M) | (15.6M) |
| Accounts Receivables | 5.54M | 5.53M | 10.26M | (5.42M) | (36.23M) |
| Inventory | (10.62M) | 4.6M | 975K | (2.59M) | (3.44M) |
| Accounts Payables | 0 | 34.46M | (46.95M) | (20.46M) | 12.1M |
| Other Working Capital | 13.17M | (8.46M) | (2.53M) | 3.72M | 11.97M |
| Other Non-Cash Items | (194.35M) | 141.53M | 1.38M | 17.79M | 12.51M |
| Operating Cash Flow | (190.43M) | (319.16M) | (180.15M) | (28.5M) | 33.28M |
| Capital Expenditures | (20.79M) | (14.32M) | (5.71M) | (5.49M) | (19.02M) |
| Acquisitions (Net) | 0 | (127M) | (8.11M) | 0 | (32.86M) |
| Purchases of Investments | 0 | 0 | (47.67M) | (66.3M) | (55.68M) |
| Sales of Investments | 0 | 0 | 17.77M | 41.66M | 46.03M |
| Other Investing Activities | (11.39M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (20.79M) | (141.33M) | (43.73M) | (30.13M) | (61.52M) |
| Debt Repayment | (13.47M) | (3.29M) | 42.95M | (3.23M) | (3.66M) |
| Common Stock Issued | 442.68M | 197.66M | 143M | 46.5M | 51.69M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 64.51M | 2.95M | 285K | 891K | 0 |
| Financing Cash Flow | 493.73M | 197.32M | 186.24M | 44.16M | 48.03M |
| Effect of Forex Changes | 0 | 0 | (87K) | 0 | 0 |
| Net Change in Cash | 282.51M | (263.17M) | (37.72M) | (14.47M) | 19.79M |
| Free Cash Flow | (211.22M) | (333.48M) | (185.86M) | (33.99M) | 14.26M |
GeneDx Holdings Corp.
NASDAQ:WGS
Intrinsic Alpha fair value
Locked
Current Price
$51.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.